Navigation Links
Sinovac to Host Conference Call to Report Fourth Quarter and Full Year 2010 Audited Financial Results
Date:3/28/2011

BEIJING, March 28, 2011 /PRNewswire-Asia/ -- Sinovac Biotech Ltd. (Nasdaq: SVA), a leading provider of vaccines in China, today announced that it will release its audited financial results for the fourth quarter and full year ended December 31, 2010 before market on Thursday, March 31, 2011.  The Company will host a conference call on Thursday, March 31, 2011 at 8:00 a.m. EDT (March 31, 2011 at 8:00 pm China Standard Time) to review the Company's financial results and provide an update on recent corporate developments.

To access the conference call, please dial 1-877-407-4018 (USA) or 1-201-689-8471 (international).  A replay of the call will be available from 11:00 a.m. ET on March 31, 2011 to April 14, 2011 at midnight. To access the replay, please dial 1-877-870-5176 (USA) or 1-858-384-5517 (international) and reference the account number 3055 and the access code 369626.

A live audio webcast of the call will also be available from the Investors section on the corporate web site at www.sinovac.com. A webcast replay can be accessed on the corporate website beginning March 31, 2011 and the replay will remain available for 30 days.

About SinovacSinovac Biotech Ltd. is a China-based biopharmaceutical company that focuses on the research, development, manufacture and commercialization of vaccines that protect against human infectious diseases including hepatitis A, seasonal influenza, H5N1 (bird flu) pandemic influenza and H1N1 influenza. In 2009, Sinovac was the first company worldwide to receive approval for its H1N1 influenza vaccine, PANFLU.1, and has received orders from the Chinese Central Government pursuit to the government stockpiling program. The Company is developing a number of new vaccine products, including vaccines for pneumococcal conjugate, enterovirus 71 (EV71) (against Hand, Foot & Mouth Disea
'/>"/>

SOURCE Sinovac Biotech Ltd.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Sinovac Participates in Two Investor Conferences in November
2. Sinovac to Participate at 2010 Shanghai CPhI Exhibition
3. Sinovac to Present at 2010 UBS Global Specialty Pharmaceuticals Conference
4. Sinovac Reports Unaudited First Quarter 2010 Financial Results
5. Sinovac to Host Conference Call to Report First Quarter 2010 Financial Results
6. Sinovac Announces Upsizing and Pricing of Common Share Offering
7. Sinovac Files Clinical Trial Application with SFDA for Vaccine Against Hand, Foot, and Mouth Disease
8. Sinovacs CEO Weidong Yin Presented with Annual Innovation Award by China Central Television
9. Sinovac Establishes Joint Venture to Expand Human-Use Vaccine Development and Manufacturing Capabilities
10. Sinovac Reports Unaudited Third Quarter 2009 Financial Results
11. Sinovac Obtains Third H1N1 Vaccine Order from Chinese Central Government
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/29/2015)... N.C. , May 29, 2015 ... affairs function into roles involving clinical development, regulatory ... its responsibilities have grown, Medical Affairs has faced ... as a global group. And while its importance ... it challenging to identify strong performance metrics to ...
(Date:5/29/2015)... , May 29, 2015 In recent ... the availability of Big Data that can generate valuable ... come with utilizing Big Data have caused the biopharmaceutical ... other industries. According to a recent ... participants already have a Big Data team or function ...
(Date:5/29/2015)... , May 29, 2015 ... company, today announces that an abstract on the latest ... inhibitor of the Axl receptor tyrosine kinase, and BGB10C9, ... BerGenBio, has been published in conjunction with the 2015 ... Chicago , May 29 - June ...
(Date:5/29/2015)... 2015 GeneWEAVE, Inc ., ... announced that initial feasibility data supporting the use ... susceptibility testing from positive blood cultures will be ... 2015 in New Orleans, LA. The Company’s Smarticles™ ... that can quickly detect bacteria and assess antibiotic ...
Breaking Biology Technology:Creating an Effective Pharmaceutical Medical Affairs Group with Global Capabilities 2New Study Details Current & Future Big Data Trends Across Medical Affairs Functions 2BGB324 and BGB10C9 Show Promise in Models of Pancreatic Cancer 2BGB324 and BGB10C9 Show Promise in Models of Pancreatic Cancer 3Data Highlighting GeneWEAVE’s Smarticles™ Technology to be Presented at the 115th General Meeting of the American Society for Microbiology (asm2015) 2Data Highlighting GeneWEAVE’s Smarticles™ Technology to be Presented at the 115th General Meeting of the American Society for Microbiology (asm2015) 3
... Corp.,(TSX, FSE: "HBP") today announced financial results for the first quarter,of ... - Subsequent to the first quarter, the Company ... of common shares, subject to closing, ... Segal remaining the Company,s Chief Executive ...
... two important surgical tools: Baxter,s ... human thrombin and Pfizer,s GELFOAM, ... announced the Food and Drug Administration approval of,GELFOAM(R) Plus ... Plus is the only available hemostasis kit that contains,Pfizer,s ...
... Lilly to Acquire Exclusive Rights to Novel Late-Stage Molecule for ... ... 17 ,Eli Lilly and Company (NYSE: LLY ) and ... have entered into a licensing and,development agreement granting Lilly exclusive ...
Cached Biology Technology:Helix BioPharma announces Q1 2008 financial results 2Helix BioPharma announces Q1 2008 financial results 3Helix BioPharma announces Q1 2008 financial results 4Helix BioPharma announces Q1 2008 financial results 5Helix BioPharma announces Q1 2008 financial results 6Helix BioPharma announces Q1 2008 financial results 7Helix BioPharma announces Q1 2008 financial results 8Helix BioPharma announces Q1 2008 financial results 9Helix BioPharma announces Q1 2008 financial results 10Helix BioPharma announces Q1 2008 financial results 11Baxter Announces FDA Approval of GELFOAM(R) Plus Hemostasis Kit 2Baxter Announces FDA Approval of GELFOAM(R) Plus Hemostasis Kit 3Baxter Announces FDA Approval of GELFOAM(R) Plus Hemostasis Kit 4Lilly and BioMS Medical Announce Global Licensing and Development Agreement 2Lilly and BioMS Medical Announce Global Licensing and Development Agreement 3Lilly and BioMS Medical Announce Global Licensing and Development Agreement 4Lilly and BioMS Medical Announce Global Licensing and Development Agreement 5Lilly and BioMS Medical Announce Global Licensing and Development Agreement 6
(Date:5/29/2015)... -- Research and Markets ( http://www.researchandmarkets.com/research/2w6zgs/facial ) has ... Market by Solution, by Software, by Hardware, by ... report to their offering. The last ... more efficient and cost effective. This has helped ... the commercial sector. The development of 3D facial ...
(Date:5/28/2015)... 2015 Industry analyst firm n-tech Research ... titled "Markets for Self-Healing Materials: 2015-2022." According to the ... vascular systems, biomaterials, relevant shape memory materials and ... billion by 2020. The report is ... smart materials. Other recent n-tech reports have included studies ...
(Date:5/27/2015)...   Codonics (codonics.com), a global ... documentation solutions and Omnicell  (omnicell.com), a ... is pleased to announce their state of ... System® (SLS), an award-winning FDA class 2 ... Anesthesia Workstation, helps prevent medication errors, streamlines ...
Breaking Biology News(10 mins):Global advanced Facial Recognition Market Expected to Grow From $2.77 Billion in 2015 to $6.19 Billion in 2020, at an Estimated CAGR of 17.4% 2The Market for Self-Healing Materials to Reach $2.7 Billion by 2020 Says New n-tech Research Study 2The Market for Self-Healing Materials to Reach $2.7 Billion by 2020 Says New n-tech Research Study 3Codonics and Omnicell Expand Partnership 2Codonics and Omnicell Expand Partnership 3Codonics and Omnicell Expand Partnership 4
... described fossil whales---a pregnant female and a male of the ... insights into how whales made the transition from land to ... 2000 and 2004 and studied at the University of Michigan, ... online journal PLoS . U-M paleontologist Philip Gingerich, ...
... In 2005, a woman who had trouble sleeping asked ... sleep disorders specialist at the Mayo Clinic campus in ... interrupts sleep because of unpleasant sensations in the legs ... relieved by movement. Restless legs syndrome affects ...
... State University already have shown that gardening can offer enough ... In research to be published in February in the journal ... health benefits of gardening is keeping older hands strong and ... older adults who are gardeners have better hand strength and ...
Cached Biology News:Early whales gave birth on land, fossil find reveals 2Mayo Clinic researchers suspect a novel gene is causing restless legs syndrome in a large family 2Gardening gives older adults benefits like hand strength and self-esteem 2